NextCODE Health
Founded Year
2013Stage
Acquired | AcquiredAbout NextCODE Health
NextCODE Health is developing a gene sequence analysis platform and database architecture that enables clinicians and researchers around the globe to use the full power of next-generation sequencing data to better diagnose and treat disease. The company's solutions combine the only whole genome analysis system developed at population scale with access to the largest clinical genetics reference database in the world.
Missing: NextCODE Health's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: NextCODE Health's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing NextCODE Health
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
NextCODE Health is included in 1 Expert Collection, including Digital Health.
Digital Health
13,069 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Latest NextCODE Health News
Jun 23, 2020
Amber Tong Editor Just five years after WuXi engineered a deal to merge its genome center with NextCODE Health, the WuXi NextCODE brand is becoming history as the company cuts off the Chinese operations and focuses on the US, Iceland and Ireland. The new name, Genuity , erases all references to WuXi NextCODE’s storied history. The US and Iceland offices of the genomics company were spun out of deCODE Genetics after it got acquired by Amgen — with its own twists and turns. Its $400 million expansion into Ireland took place in late 2018, complete with the acquisition of Genomics Medicine Ireland. Whereas WuXi NextCODE was headquartered in Shanghai, Genuity will shift its command center to Boston. According to the company, the reason for cutting off its China ties is purely legal. China tightened its Human Genetics Resource Regulation and other rules in mid-2019, and NextCODE was among many companies that were designated as foreign entities — erecting serious constraints to their work and possibility for growth overnight. The capabilities they had in Shanghai were “valued by a number of our international customers,” said Rob Brainin, whose cards now say CEO of Genuity. Now that it’s gone, they have poured more resources in both Dublin and Woburn, MA, to do some of the things their Chinese colleagues used to handle. Between the three remaining sites, Genuity has more than 200 employees sourcing, consolidating and analyzing genomic data for partners. Recently, they’ve begun supporting Irish research institutions in sequencing the genomes of Covid-19 patients. Official separation from the Shanghai office is slated for later this year, although Genuity is already considering what to do with it. Despite the shakeup, its investor base actually remains the same, featuring some marquee names such as Temasek, ARCH and Sequoia Capital. None of them, Brainin felt compelled to add, will have access to sensitive information or internal data. As he clarified in an email: WuXi NextCODE is not owned by WuXi AppTec or other WuXi companies. Since 2017, WuXi NextCODE has been operating as an independent private company with former WuXi PharmaTech shareholders serving among the company’s many investors. AUTHOR Jason Mast Associate Editor As Covid-19 began disrupting global trade early this spring and spurred countries such as India to restrict exports of drugs that could be useful against the virus, the Trump Administration began talking publicly about the need to expand the US’ capacity to make pharmaceutical ingredients onshore. That’s when a pair of private equity firms apparently saw a financial opportunity. Lincoln Equities Group and H.I.G. Realty Partners announced yesterday that they have acquired a 1.2 million square-foot pharmaceutical campus near Princeton, New Jersey from Bristol Myers Squibb. They are now marketing it in terms consistent with the administration’s rhetoric. Read More June 23, 2020 01:00 AM EDTUpdated 04:47 AM This is an important day for Sanofi. For years now it’s been forced to consider deep doubts surrounding its ability to execute in R&D , with a long history of slow-footed clinical advances and a weak in-house pipeline. Its cutting-edge innovation projects came from Regeneron, which it’s been separating from. And today, during R&D day, Sanofi CEO Paul Hudson as well as R&D chief John Reed hope to leave that all behind with a forceful presentation on the pharma giant’s newfound nimbleness and capacity to build an exciting late-stage pipeline with several top projects in hand. Keep reading Endpoints with a free subscription Unlock this story instantly and join 84,300+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE John Carroll Editor & Founder Back at the start of January last year, Poseida Therapeutics thought it had an IPO-worthy game plan that would sell on Wall Street. Instead, with the market in something of a dyspeptic mood, the San Diego-based startup with its next-gen approach to cell and gene therapy switched to a Series C mega round and dropped the IPO. Until now, while the market is running red hot for all things drug-development related. And on Friday Nasdaq loaded up a new round of biotech IPOs to sell to investors. Keep reading Endpoints with a free subscription Unlock this story instantly and join 84,300+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE John Carroll Editor & Founder Back at the end of last March, with the world locking down in the face of a pandemic, Sanofi tied up with mRNA biotech Translate Bio an a hastily patched-up Covid-19 deal that came with no money down on top of their original pact. Now, as new Sanofi CEO Paul Hudson plants the corporate flag on a quest to do a makeover of their slow-mo corporate image (see related story ), Sanofi widened its embrace with another add-on: And this one comes with the considerable panache of a big upfront to cover a next-gen drug technology. Keep reading Endpoints with a free subscription Unlock this story instantly and join 84,300+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE John Carroll Editor & Founder Merck has come out of its corner with a 1-2 late-stage punch aimed at one of Pfizer’s biggest franchises. And they’re rolling the late-stage data out around the world to regulators. Looking to prove that it’s more than just a Keytruda company in R&D, Merck today laid out upbeat top-line results for 2 Phase III studies of V114 , their 15-valent rival to Prevnar 13, which has begun to stagnate a little with its $5.8 billion market. That is still Pfizer’s top-selling drug, with a troubled Ibrance coming up in second place. Keep reading Endpoints with a free subscription Unlock this story instantly and join 84,300+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE Amber Tong Editor Last November, Nisa Leung found herself catching up with Margaret Chan in a conference at Beijing, wondering when the next pandemic may be. Leung, now a managing partner at Qiming , had just graduated from business school at Stanford when she was asked to introduce infectious disease experts to Chan, then Hong Kong’s Secretary of Health. The year was 2003; the city was grappling with a local outbreak of a deadly coronavirus disease — later named the severe acute respiratory syndrome, or SARS — that began with a patient zero from mainland China. “I still remember very clearly that back then we tried to develop a diagnostic test in China and we kind of just didn’t have the capability,” Leung said. “And so we had to send the strains to the US for a company to develop it for us.” Keep reading Endpoints with a free subscription Unlock this story instantly and join 84,300+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE
NextCODE Health Frequently Asked Questions (FAQ)
When was NextCODE Health founded?
NextCODE Health was founded in 2013.
Where is NextCODE Health's headquarters?
NextCODE Health's headquarters is located at Cambridge.
What is NextCODE Health's latest funding round?
NextCODE Health's latest funding round is Acquired.
Who are the investors of NextCODE Health?
Investors of NextCODE Health include WuXi AppTec.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.